DUAL-SPECIFIC PROTEIN

The present invention addresses the problem of providing a new drug that, with respect to autoimmune diseases or blood cancer, is for preventing, suppressing the advance of symptoms, suppressing recurrence, or treating such diseases. The inventors of the present invention conducted extensive studies...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SHIBAYAMA, Shiro, TEZUKA, Tomoya
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention addresses the problem of providing a new drug that, with respect to autoimmune diseases or blood cancer, is for preventing, suppressing the advance of symptoms, suppressing recurrence, or treating such diseases. The inventors of the present invention conducted extensive studies, and came to focus on a PD-1/CD4 dual-specific protein as a substance that can solve the foregoing problem, leading to completion of the present invention. The PD-1/CD4 dual-specific protein according to the present invention is configured to reduce the induction of generation or release of cytokine that occurs when the protein is administered. As a result, it can be expected that infusion reaction or cytokine release syndrome that could occur upon administration of the protein is suppressed.